First Liquid Biopsy for Neurologic Diseases

18 – 30% of cases of Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease are misdiagnosed.

The FBB Biomed blood test measures newly discovered RNA biomarkers for these neurologic diseases to increase diagnostic accuracy at the time of first diagnosis. This is the world’s first liquid biopsy for neurologic diseases.

The Challenge

Neurologic Misdiagnosis

Screening protocols for neurologic diseases – including Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), and Alzheimer’s Disease (AD) – currently rely on imprecise diagnostic methods and fail to provide a prognostic view to health outcomes.
Research indicates that up to a third of cases are misdiagnosed within this disease group, leading to incorrect treatment protocols and the use of wrong medications.

Our Solution

RNA Biomarkers

FBB Biomed’s newly discovered RNA biomarkers increase diagnostic accuracy at the time of screening by providing a molecular diagnostic for MS, PD, and AD.
FBB Biomed’s pre-clinical research has demonstrated significant potential for earlier, more accurate diagnosis of these diseases.

Our Product

NGS-based Blood Test

FBB Biomed’s proprietary reagent and bioinformatics software power our blood test based on RNA biomarkers. Our test provides neurologists with a liquid biopsy for the diagnosis of Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease.

Our test runs on standard laboratory sequencing equipment and protocols. No new hardware or processes required.

Actionable Clinical Utility

Use Cases

Early Diagnosis

Is this patient suffering from neurodegeneration?

Differential Diagnosis

Which neurologic disease does this patient have?

Patient Monitoring

How effective has the prescribed therapy been so far?

From the Scientific Community

What Others Say About Us